Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4195 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Genomics BioSci & Tech Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomics BioSci & Tech Co FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomics BioSci & Tech Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Genomics BioSci & Tech Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomics BioSci & Tech Co (TPE:4195) has a FCF Margin % of -38.43% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genomics BioSci & Tech Co and its competitors. According to the industry distribution chart, Genomics BioSci & Tech Co ranks #348 out of 954 companies in the Biotechnology industry, placing it in the top 36.5%.
Is Genomics BioSci & Tech Co's FCF Margin % too high?
Genomics BioSci & Tech Co's current FCF Margin % is -38.43%. Based on the distribution chart, Genomics BioSci & Tech Co ranks #348 out of 954 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genomics BioSci & Tech Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genomics BioSci & Tech Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomics BioSci & Tech Co ranks #348 out of 954 companies for FCF Margin %. This puts Genomics BioSci & Tech Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genomics BioSci & Tech Co and its competitors. Genomics BioSci & Tech Co's current FCF Margin % is -38.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomics BioSci & Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Genomics BioSci & Tech Co (TPE:4195) is currently considered Possible Value Trap. The stock's GF Value™ is NT$34.15, compared to a current price of NT$15.35 — trading 55.1% below its estimated fair value. The current FCF Margin % is -38.43%. Genomics BioSci & Tech Co's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Genomics BioSci & Tech Co (TPE:4195), the current FCF Margin % is -38.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomics BioSci & Tech Co (TPE:4195) Overvalued in 2026?
Based on GuruFocus' analysis, Genomics BioSci & Tech Co stock appears to be undervalued.
The current stock price of NT$15.35 is trading 55.1% below its estimated GF Value™ of NT$34.15.
GuruFocus considers Genomics BioSci & Tech Co to be Possible Value Trap.
Key valuation signals for TPE:4195:
FCF Margin %: -38.43%
GF Value™: NT$34.15 vs. price of NT$15.35 (55.1% below fair value)
No single metric tells the full story. See the TPE:4195 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomics BioSci & Tech Co Ltd is a Taiwan based commercial genome sequencing company formed to develop medical genetic testing. The services of the company include Sanger sequence service, Synthesis Service and Genomic Service.
42GF Score
Get the complete analysis for TPE:4195
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4195 has been successfully added to your 
